Why Haemonetics Stock Dived by 15% Today

Haemonetics (NYSE: HAE) had a day to forget on Tuesday. Following the release of its latest quarterly earnings, the blood and plasma collection specialist's stock fell by over 15%.

Haemonetics booked revenue of $240 million for its second quarter of fiscal 2022, which was 15% higher on a year-over-year basis. Going in the opposite direction, but not alarmingly so, was non-GAAP (adjusted) net income. This dipped by 3% compared to the year-ago period to land at $30.7 million, or $0.60 per share.

Image source: Getty Images.

Source Fool.com